Expert Interview
A Third Opinion: Discussing the use of GLP-1 agonists and the potential of Neurogastrx Inc. NG101 (metopimazine mesylate), currently being studied to limit nausea and vomiting side effects caused by GLP-1 agonist medications.
Ticker(s): NEUROGASTRX INC., NVO, LLY
Crozer Health
- Treats 700 patients with Obesity per year
- able to discuss your thoughts on the potential of a bi-weekly GLP-1 receptor agonist injection and the 30 week data from the Phase IIb trial (data was linked and will be included in calendar invite
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
